Drug Trial Radar · NCT07750574
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
105
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Nov 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Chengdu Zenitar Biomedical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn which of three different doses of Flonoltinib Maleate taken by mouth daily works best to treat adult patients with myelofibrosis in whom the most common approved therapy has failed to adequately control the disease. It will also learn about the safety of the three different daily doses of Flonoltinib Maleate. The main questions it aims to answer are: Which dose is the best at controlling the symptoms and signs of organ damage caused by myelofibrosis? What medical problems do participants have when taking the three different doses of Flonoltinib Maleate? Researchers will compare the three different doses of Flonoltinib Maleate to see which dose is best to treat patients with myelofibrosis. Participants will: Take Flonoltinib Maleate every day for as long as it seems to be of benefit to them in terms of controlling myelofibrosis. Visit the clinic for checkups and tests after giving fully informed written consent confirming that they would like to consider entering the study. Visit the clinic for checkups and tests when on the study once every 2 weeks for the first 2 months, every 4 weeks after that, and when coming off study therapy. Keep a diary of their symptoms.
Conditions
- Myelofibrosis
- Myelofibrosis Due to and Following Polycythemia Vera
- Myelofibrosis Transformation in Essential Thrombocythemia
- Myelofibrosis With High Molecular Risk Mutations
- Myelofibrosis With Myeloid Metaplasia
- Myelofibrosis, Post ET
- Myelofibrosis, Post PV
- Myelofibrosis, Primary
- Myelofibrosis; Anemia
- Myelofibrosis,MF
- Myelofibrosis (PMF)
- Myeloid Metaplasia
Interventions
Flonoltinib Maleate orallyDrug
Dose of Flonoltinib Maleate will be 50mg daily
Flonoltinib Maleate orallyDrug
Dose of Flonoltinib Maleate will be 75mg daily
Flonoltinib Maleate orallyDrug
Dose of Flonoltinib Maleate will be 100mg daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with ≥35% reduction in spleen volume as assessed by imaging from baseline to week 24Time frame: Baseline and at 24 weeks on study
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.